ClinicalTrials.Veeva

Menu

Study on Acupuncture Treatment of Chronic Airway Diseases(Asthma and Chronic Obstructive Pulmonary Disease)

H

Henan University of Traditional Chinese Medicine

Status

Not yet enrolling

Conditions

COPD Exacerbation Acute
Asthma Acute

Treatments

Behavioral: Acupuncture
Behavioral: Sham Acupuncture

Study type

Interventional

Funder types

Other

Identifiers

NCT06869525
TCM for Chronic Airway Disease

Details and patient eligibility

About

For patients in the acute phase of chronic airway diseases, on the basis of guideline-directed treatment, the experimental group was given acupuncture treatment, while the control group was given sham acupuncture treatment. The treatment lasted for one week, followed by a 13-week follow-up. For asthma and COPD, PEF and CAT were respectively used as the primary outcome measures to evaluate the clinical efficacy and safety of acupuncture. Based on the improvement of the primary outcome measures, the advantageous population was identified. The mechanism by which acupuncture reduces airway mucus hypersecretion was preliminarily explained.

Full description

This study was a multicenter, randomized, double-blind, controlled trial. A total of 336 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and 240 patients with acute attack of asthma were included. On the basis of guideline-directed treatment, the experimental group received acupuncture treatment, while the control group was given sham acupuncture treatment. For patients with AECOPD, the acupoints selected were Zhongfu, Dingchuan, Tiantu, Fenglong, and Feishu. For patients with acute attack of asthma, the acupoints selected were Dingchuan, Zhongfu, Tiantu, Feishu, and Kongzui. The acupoints were connected to electroacupuncture and treated for 30 minutes. The control group received sham acupuncture treatment. The acupoints were located 5 to 10 mm away from the actual acupoints, and the needles were inserted superficially through the skin. The acupoints were connected to electroacupuncture but without electricity. The treatment lasted for 30 minutes, once a day, for one week. Follow-up was conducted for 13 weeks. For COPD, the COPD Assessment Test (CAT) was the primary outcome measure, and the secondary outcome measures included the mMRC scale, assessment of airway mucus hypersecretion, CT assessment of airway mucus, basic vital signs, clinical symptom scores, use of control medications and antibiotics, acute exacerbation status, hospitalization time, tracheal intubation rate, and arterial blood gas. For asthma, the peak expiratory flow (PEF) was the primary outcome measure, and the secondary outcome measures included the Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), assessment of airway mucus hypersecretion, CT assessment of airway mucus, basic vital signs, clinical symptom scores, use of control medications and antibiotics, acute attack status, hospitalization time, and fractional exhaled nitric oxide (FeNO). The clinical efficacy and safety of acupuncture were evaluated. The population with advantages was identified based on the improvement of the primary outcome measures. The mechanism of acupuncture in reducing airway mucus hypersecretion was preliminarily explained.

Enrollment

576 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Meets the diagnostic criteria for acute attack of asthma/AECOPD;
  • Age range from18 years to 80 years(asthma) and 40 yesrs to 80 years(COPD);
  • The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form.

Exclusion criteria

  • Patients with combined pulmonary abscess, pulmonary interstitial fibrosis, active pulmonary tuberculosis, bronchiectasis and other pulmonary diseases;
  • Patients with severe cardiovascular and cerebrovascular diseases (such as malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, grade 3 or above cardiac function, stroke, cerebral hemorrhage, etc.);
  • Patients with severe liver diseases (such as liver cirrhosis, portal hypertension and bleeding caused by esophageal and gastric fundus varices) and severe kidney diseases (such as dialysis, kidney transplantation, etc.);
  • Patients with impaired consciousness or various mental disorders who are unable to communicate normally;
  • Pregnant and lactating women;
  • Those who are currently participating in other clinical trials within 1 month before enrollment;
  • Patients with contraindications to acupuncture (such as severe allergic or infectious skin diseases);

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

576 participants in 2 patient groups

Acupuncture group for Asthma Acute/AECOPD
Experimental group
Description:
Patients in the Asthma Acute/AECOPD experimental group were treated with Acupuncture
Treatment:
Behavioral: Acupuncture
Sham Acupuncture group for Asthma Acute/AECOPD
Sham Comparator group
Description:
Patients in the Asthma Acute/AECOPD experimental group were treated with Sham Acupuncture
Treatment:
Behavioral: Sham Acupuncture

Trial contacts and locations

0

Loading...

Central trial contact

Yang Xie, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems